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Abstract
 
The granule exocytosis cytotoxicity pathway is the major molecular mechanism for cytotoxic
T lymphocyte (CTL) and natural killer (NK) cytotoxicity, but the question of how these cyto-
toxic lymphocytes avoid self-destruction after secreting perforin has remained unresolved. We
show that CTL and NK cells die within a few hours if they are triggered to degranulate in the
presence of nontoxic thiol cathepsin protease inhibitors. The potent activity of the imper-
meant, highly cathepsin B–specific membrane inhibitors CA074 and NS-196 strongly impli-
cates extracellular cathepsin B. CTL suicide in the presence of cathepsin inhibitors requires the
granule exocytosis cytotoxicity pathway, as it is normal with CTLs from 
 
gld
 
 mice, but does not
occur in CTLs from perforin knockout mice. Flow cytometry shows that CTLs express low to
undetectable levels of cathepsin B on their surface before degranulation, with a substantial
rapid increase after T cell receptor triggering. Surface cathepsin B eluted from live CTL after
degranulation by calcium chelation is the single chain processed form of active cathepsin B.
Degranulated CTLs are surface biotinylated by the cathepsin B–specific affinity reagent NS-196,
which exclusively labels immunoreactive cathepsin B. These experiments support a model
in which granule-derived surface cathepsin B provides self-protection for degranulating
cytotoxic lymphocytes.
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Introduction
 
In vitro studies of cytotoxic lymphocytes have demon-
strated that they utilize two molecular pathways to kill tar-
get cells (1). In vivo studies have shown that both of these
pathways play major roles in host defense against infections
and tumors, T cell homeostasis, and prevention of au-
toimmunity (2–5). In one pathway, Fas on target cells is
cross-linked by effector cell Fas ligand (FasL),
 
*
 
 triggering a
relatively well-studied death pathway involving caspase ac-
tivation. The second, and normally dominant, pathway in-
volves a polarized secretion of preformed perforin and
granzymes by effector cell granule exocytosis, leading to
rapid target caspase activation as well as a caspase-indepen-
dent death pathway (6).
Although the basic granule exocytosis mechanism was
outlined in the 1980s, an interesting but unresolved issue
arose from early findings that CTLs themselves do not nor-
mally die while killing target cells, as shown by the demon-
stration that one CTL can kill multiple targets within a few
hours (7). Thus, if perforin and granzymes are secreted in
high enough local concentrations to kill target cells, why
are the cytotoxic lymphocytes themselves not killed? This
issue has been addressed by a number of laboratories with-
out a completely satisfactory explanation (8). There is evi-
dence that cytotoxic lymphocytes may have an inherent re-
sistance to the cytotoxic mediators, particularly perforin. In
support of this idea, in vitro–cloned CTLs bearing surface
antigens recognized by other CTLs are generally resistant
to lytic attack relative to tumor targets (9–11). Cloned
CTLs were likewise shown to be relatively resistant to lysis
induced by CTL granule extracts as well as purified per-
forin (11–14). The molecular basis for CTL resistance to
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Abbreviations used in this paper: 
 
ECL, enhanced chemiluminescence;
FasL, Fas ligand; HRP, horseradish peroxidase.  
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perforin remains undefined. One study reported that per-
forin binding to CTL membranes was defective relative to
tumor membranes (15), whereas another showed equiva-
lent perforin binding but provided evidence for a different
conformation of membrane-bound perforin on CTLs (14).
Although these studies argue for some kind of protection
mechanism for CTLs against their own lethal damage, they
also show clear examples of cloned CTLs being readily
lysed by other CTLs. Thus, in vivo–derived CTLs and nor-
mal lymphocytes were reported to be equally susceptible to
CTL attack (16). Cloned CTL specific for a defined pep-
tide restricted by self–MHC class I were shown to kill
themselves in a fratricidal process in the presence of the
specific peptide (17–19). Fratricide via the granule exocy-
tosis pathway has been shown to limit viral antigen expres-
sion in short-term cultured CD8
 
  
 
T cells from HTLV-1–
infected patients (20). Thus, CTLs can clearly sometimes
kill other CTLs, and their relative resistance to granule me-
diators in vitro does not provide a satisfactory explanation
for their self-protection during target death.
In our approach to the issue of cytotoxic lymphocyte
self-protection, we reasoned that protection is most needed
locally at the effector membrane at the time of granule exo-
cytosis and consequently, a granule component was an ex-
cellent candidate. Because it is clear that cytotoxic lympho-
cyte secretory granules contain a full complement of
lysosomal enzymes (21), it was interesting to note that the
lysosomal thiol cathepsin endoproteases, particularly cathep-
sin B, can associate with some tumor cell surfaces where
they maintain proteolytic activity in the extracellular envi-
ronment (22, 23). In the process of forming membrane
channels, perforin goes through an intermediate mem-
brane-associated stage in which it is highly susceptible to
proteolysis before polymerization into a more resistant
pore-forming complex (14, 24–26). Because this mem-
brane-associated perforin should be particularly vulnerable
to a protease associated with the same membrane, we hy-
pothesized that a membrane-associated granule cathepsin,
expressed locally on the effector cell surface after exocyto-
sis, could provide efficient self-protection to effector cells.
This study shows that in the presence of nonmembrane
permeable cathepsin B inhibitors, cytotoxic lymphocytes
undergo a rapid perforin-dependent death when degranu-
lation is triggered, and TCR cross-linking leads to the rapid
appearance of active, surface-bound cathepsin B on CTLs.
These results provide evidence that proteolysis by surface
cathepsin B provides cytotoxic lymphocyte self-protection.
 
Materials and Methods
 
Antibodies and Reagents.
 
Purified hamster anti–mouse CD3
(2C11), hamster IgG, anti–mouse CD45, anti–CD4-FITC, anti–
CD8-PE, anti–human CD28, avidin-FITC anti–mouse IgG-
FITC, anti–mouse Fas (Jo-2), and recombinant IL-7 were pur-
chased from BD Biosciences. Purified mouse anti–human CD3
(UCHT1) was provided by Julie Titus (NCI, Bethesda, MD).
Mouse anti–human cathepsin B antibody was purchased from
Oncogene Research Products. Rat anti–mouse perforin was pur-
chased from Kamiya Biomedical Company and goat anti–rat
IgG-horseradish peroxidase (HRP) was purchased from Southern
Biotechnology Associates, Inc. Mouse anti–human cathepsin L
was purchased from Transduction Laboratories. Recombinant
human IL-2 was purchased from Roche Diagnostics. The human
liver cathepsin B, protease inhibitors ZLLY-DMK, ZFA-FMK,
GF-DMK, ZFA(
 
 
 
)-FMK, and Bi-FA-FMK were purchased
from Enzyme System Products, dissolved as stock solutions of 50
mM in DMSO and stored at 
 
 
 
70
 
 
 
C. CA074 and CA074Me
were obtained from the Peptide Institute. CLIK 148 was pro-
vided by Giovanni Tonon (NCI, Bethesda, MD). Human cysta-
tin C was purchased from Research Diagnostics. Concanamycin
A was obtained from Alexis Biochemicals Corp. EDTA, EGTA,
and dextran were purchased from Sigma-Aldrich. Hoechst
33342, propidium iodide, and Streptavidin-HRP were purchased
from Molecular Probes. Protein G beads, Hybond enhanced
chemiluminescence (ECL) nitrocellulose membrane, and Hyper-
film ECL were obtained from Amersham Biosciences.
 
Lymphocytes.
 
C57Bl/6J (B6), BALB/c, and perforin-deficient
C57BL/6-Pfp
 
tm1Sdz 
 
mice were obtained from The Jackson Labo-
ratory. FasL-defective B6Smn.C3H-Fasl
 
gld 
 
were provided by Paul
Chrobak (NCI, Bethesda, MD). The murine lymphomas EL4
and L1210 were maintained in RPMI 1640 supplemented with
10% FCS, 100 IU penicillin, and 10 
 
 
 
g/ml streptomycin. Mouse
CTLs were prepared by harvesting spleen cells from B6 or mutant
mice, lysing with ACK (Biofluids), and culturing in 24-well
plates at 2 
 
  
 
10
 
6 
 
cells/well in RPMI 1640 containing 10% FCS
and 25 
 
 
 
M 2-ME with 
 
 
 
-irradiated BALB/c cells (10
 
6 
 
cells/
well). After 5 d at 37
 
 
 
C in a 5% C0
 
2 
 
incubator, viable cells were
isolated by Lympholyte (Cedarlane Laboratories) and cultured for
an additional 48 h in the same medium containing 0.8 ng/ml rIL-7
and 25 U/ml rIL-2. CD8
 
  
 
and CD4
 
  
 
T cells were purified by
positive magnetic bead selection using CD8 and CD4 microbeads
and the VarioMac cell sorting system (Miltenyi Biotec). For CTL
activity assays, BALB/c spleen cells from 2 
 
  
 
10
 
7 
 
EL-4 cells
primed intraperitoneally 10–14 d before harvest were cultured for
5 d as described above, with C57Bl/6J spleen cells as stimulators.
Human lymphocytes were used for most of the experiments in
this study. PBMC were purified by Ficoll-Paque (Amersham
Biosciences) from buffy coat or lymphocyte apheresis prepara-
tions obtained from normal healthy donors. For most experi-
ments, PBMC were stimulated with 2.5 
 
 
 
g/ml PHA (Sigma-
Aldrich) or irradiated PBMC from HLA-mismatched donors at a
2:1 responder/stimulator ratio, followed by culture for 7–10 d in
culture medium containing RPMI 1640 supplemented with 10%
FCS, 20 U/ml rIL-2, antibiotics, and nonessential amino acids.
For purification of CD4
 
  
 
and CD8
 
  
 
subsets, blasts were positively
selected magnetically with CD4 or CD8 microbeads (Miltenyi
Biotec), resulting in 
 
 
 
90% purity by flow cytometry. After puri-
fication, the blasts were maintained in culture medium with 20
U/ml rIL-2 for at least 3 d before the experiments were per-
formed. Resting peripheral CD4
 
  
 
and CD8
 
  
 
T cells were puri-
fied from PBMC by negative selection using the antibody cock-
tails in CD4
 
  
 
and CD8
 
  
 
isolation kits (Miltenyi Biotec), again
with 
 
 
 
90% purity by flow cytometry.
CD8
 
  
 
CTL clone RS-56, recognizing HTLV-1 tax peptide in
the context of HLA-A2, was provided by William Biddison (Na-
tional Institute of Neurological Disorders and Stroke, Bethesda,
MD). Human NK cells purified from human blood were acti-
vated for 6 d by culture with irradiated RPMI 8866 cells (27),
and purified using the Vario-MACS NK isolation kit (Miltenyi
Biotec) provided by Alessandra Mazzoni and David Segal, NCI,
Bethesda, MD). 
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In Vitro Suicide Experiments.
 
Flat-bottom 96-well plates were
coated with 10 
 
 
 
g/ml anti-CD3 or isotype-matched IgG in bi-
carbonate buffer, pH 8.5, overnight at 4
 
 
 
C, and then washed
with medium. Standard conditions for suicide experiments used
200 
 
 
 
l activated CD8
 
  
 
T blasts of 10
 
6 
 
cells/ml complete medium
with and without cathepsin inhibitors incubated for 4 h in a CO
 
2
 
incubator. The plates were then spun and the supernatant was re-
moved, followed by staining with 5 
 
 
 
g/ml propidium iodide or
Hoechst 33342 in HBSS for 10 min at 37
 
 
 
C before fluorescence
microscopy.
 
Flow Cytometry.
 
CD4/CD8 phenotyping was performed by
incubating 1 
 
 
 
g appropriate antibody with 10
 
6 
 
cells in 100 
 
 
 
l,
followed by washing and flow cytometry with a FACScan™ (BD
Biosciences). For cathepsin B and cathepsin L staining, CTLs
were harvested and incubated with 10 
 
 
 
g/ml anticathepsin mAbs
or control IgG for 1 h on ice. After washing, cells were incubated
with 5 
 
 
 
g/ml of FITC-anti–mouse IgG for 30 min and samples
were analyzed by flow cytometry.
 
Cytotoxicity Assays.
 
51
 
Cr-labeled B6 anti-BALB/c MLR cells
were mixed with varying numbers of L1210 cells in the presence
or absence of 10 
 
 
 
M CA074 for 4 h at 37
 
 
 
C in 5% CO
 
2 
 
in 96-
well plates (see Fig. 3, A and B). After 4 h, 100 
 
 
 
l supernatant
were harvested for counting. EL-4 target cells were labeled with
Na
 
2
51
 
Cr
 
2
 
O
 
7
 
 (200 
 
 
 
Ci in 0.5 ml HBSS plus 10% FCS) for 45 min
at 37
 
 
 
C (see Fig. 3, C–E). After washing twice with complete
medium, 10
 
4 
 
target cells were incubated with varying numbers of
BALB/c anti-B6 MLR cells in the presence or absence of 10 
 
 
 
M
CA074 for 4 h at 37
 
 
 
C in 5% CO
 
2 
 
in 96-well plates. After 4 h,
125 
 
 
 
l supernatant were harvested for counting and replaced
with 125 
 
 
 
l medium for 
 
 
 
12 h of additional incubation. As a
toxicity control for CA074, CTLs were mixed with 10 
 
 
 
M
CA074 for 16 h before carrying out cytotoxicity assays with 
 
51
 
Cr-
labeled EL-4 cells.
 
Surface Cathepsin B Characterization.
 
Human RS-56 CTLs were
incubated on wells coated with anti-CD3 or control IgG for 2 h
at 37
 
 
 
C. After washing with cold HBSS, they were incubated in
HBSS with or without 2 mM Mg-EGTA or Ca-EDTA for 10
min at 37
 
 
 
C. Supernatants were harvested, concentrated with a
Savant SpeedVac (Savant Instruments), dissolved, dialyzed, run
on a 12% reduced SDS gel, and blotted onto nitrocellulose mem-
branes. These were then incubated with 10 
 
 
 
g/ml anticathepsin
B mAb, probed with HRP-anti–mouse IgG, and developed using
ECL (Amersham Biosciences). For detection of surface cathepsin
B, CTLs were cultured on plate-bound anti-CD3 for 2 h at
37
 
 
 
C. Cells were washed with PBS and incubated with 0.5 mM
EDTA in PBS for 10 min at 37
 
 
 
C. Cells were spun down,
washed with PBS, and stained with anti-cathepsin B mAb fol-
lowed by FITC-anti–mouse IgG.
To detect the active form of cathepsin B, CTL clone RS-56
was cultured on plate-bound anti-CD3 or isotype Ig for 2 h at
37
 
 
 
C and stained with 1 
 
 
 
M membrane-impermeant biotin-
ylated cathepsin B–specific epoxysuccinyl peptide affinity label
NS196 for 45 min at 37
 
 
 
C. Cells were washed twice with HBSS
followed by staining with 10 
 
 
 
g/ml streptavidin-FITC for 45
min on ice. Samples were analyzed by flow cytometry.
To show that cathepsin B–specific affinity label NS-196 reacts
with one 32-kD protein corresponding to cathepsin B single
chain form, human CTL clone RS56 was stimulated with plate-
bound anti-CD3 or isotype Ig for 2 h at 37
 
 
 
C. Cells were har-
vested, washed twice with HBSS, and counted for cell number.
Samples with equal cell numbers were pulsed with or without 0.1
 
 
 
M NS196 for 1 h at 37
 
 
 
C and then washed twice with HBSS.
Cells were lysed with 200 
 
 
 
l lysis buffer (0.5% Triton X-100 in
HBSS) for 30 min at room temperature. Supernatants were har-
vested by centrifugation and biotinylated cathepsin B was immu-
nodepleted with 10 
 
 
 
g/ml rabbit polyclonal antihuman cathep-
sin B or rabbit Ig plus protein G beads. Supernatants were
harvested, concentrated with a Savant SpeedVac, and dissolved in
nonreducing SDS sample buffer. Samples were run on 12% SDS
gel and blotted onto a nitrocellulose membrane. For labeling
whole CTLs, cells were lysed with lysis buffer and incubated with
0.1 
 
 
 
M NS196 for 1 h at 37
 
 
 
C. The lysate proteins were precip-
itated with 3.3% TCA, washed twice with acetone, and dissolved
in HBSS. Samples were mixed with nonreducing SDS sample
buffer and run on 12% SDS gel and then blotted onto a nitrocel-
lulose membrane. The membrane was blocked with 3% nonfat
dry milk in TBST (Tris-buffered saline with 0.1% Tween 20)
overnight at 4
 
 
 
C. The membrane was incubated with Streptavi-
din-HRP (0.16 
 
 
 
g/ml in TBST) for 30 min at room temperature
and then washed three times with TBST and developed using
ECL (Amersham Biosciences).
 
Perforin Cleavage by Purified Cathepsin B.
 
B6 anti-BALB/c MLR
cells (25 
 
  
 
10
 
6
 
/ml in PBS plus 0.5 M NaCl) were freeze-thawed
six times and the supernatant was harvested by centrifugation. Ali-
quots of 1.2 
 
  
 
10
 
5 
 
cell equivalents were treated with 258 ng/ml
purified human liver cathepsin B in 50 mM phosphate buffer, pH
6.0, for various time periods, and mixed with SDS sample buffer.
Reduced 12% SDS gels were run and blotted onto a nitrocellulose
membrane. After blocking with 3% nonfat dry milk in TBST
overnight at 4
 
 
 
C, the membranes were incubated with 0.5 
 
 
 
g/ml
antiperforin mAb followed by HRP-anti–rat IgG. The blots were
developed using ECL (Amersham Biosciences).
 
Results
 
CD8
 
  
 
Blasts Undergo Rapid Suicide via Granule Exocytosis
When Cultured on Anti-CD3 in the Presence of Cathepsin In-
hibitors.
 
If thiol cathepsin endoproteases participate in cy-
totoxic lymphocyte self-protection, inhibiting them during
degranulation would be expected to induce effector cell
suicide. The experiment in Fig. 1 A shows that surface-
bound anti-CD3 induces death within 4 h of 
 
 
 
10–15% of
murine CD8
 
  
 
T cells from a primary MLR culture. How-
ever, in the presence of two irreversible inhibitors of thiol
cathepsin endoproteases, ZFA-FMK (28) and ZLLY-DMK
(29), 35–55% of these cells died, with similar numbers ob-
tained by measuring apoptotic nuclear morphology or lytic
membrane damage. These peptide-based cathepsin inhibi-
tors displayed no toxicity in the absence of CD3 cross-link-
ing (inset bars). As specificity controls for the reactivity of
these inhibitors, we used the 
 
 
 
 amino acid–containing ho-
mologue ZF(
 
 
 
)A-FMK and the cathepsin C inhibitor GF-
DMK, which contain identical reactive groups but do not
inactivate cathepsin endoproteases. These control com-
pounds failed to promote CTL death when CD3 was cross-
linked (Fig. 1 A). As additional controls, CTLs were incu-
bated on wells coated with anti-CD45, which induces
attachment without degranulation. Cathepsin inhibitors did
not promote death under these conditions (Fig. 1 A).
This TCR-induced CTL death in the presence of cathep-
sin inhibitors could be interpreted as a form of activated
cell death, which in T cells has been strongly associated 
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with the FasL/Fas death pathway. Although such activa-
tion-induced cell death is typically observed only 12–16 h
after TCR ligation, several approaches were taken to ad-
dress the relative roles of the FasL–Fas and granule exocy-
tosis pathways in this T cell death. An IgG anti-Fas mAb
that blocks the FasL–Fas death pathway (6) had no effect on
CTL death induced by anti-CD3 in the presence of the ca-
thepsin inhibitor ZLLY-DMK (Fig. 1 B). In contrast, clear
inhibition was observed in the presence of the granule pro-
ton pump inhibitor concanamycin A, which blocks the
granule exocytosis cytotoxicity death pathway (30), and in
the presence of EGTA, which blocks CTL degranulation
(31) and perforin function.
The role of the granule exocytosis pathway in this death
was additionally confirmed using T cells from perforin
knockout and 
 
gld 
 
(FasL-mutant) mice. As shown in Fig. 1 C,
activated CD8
 
  
 
T cells from the former did not show signif-
icant death when incubated on anti-CD3–coated wells in
the presence of ZLLY-DMK or ZFA-FMK, whereas the
latter showed death induction similar to control mice.
Fig. 1 D illustrates the kinetics of death in the cloned hu-
man CTL line RS-56 induced by anti-CD3 in the presence
of cathepsin inhibitor ZFA-FMK, which increases between
1 and 4 h, paralleling the secretion of granule enzymes un-
der these conditions (32). Similar results were obtained with
mouse CTL (unpublished data). To probe whether this
death is cell autonomous (suicidal) or involves an interaction
between two cells (fratricidal), we used a previous approach
for activation-induced cell death via the FasL–Fas pathway
(33). Unlike the latter case of fratricide, the activation-
induced death of CTL in the presence of cathepsin inhibitor
was not dependent on cell concentration, nor was it inhib-
ited by viscous dextran solutions that inhibit standard CTL
killing assays (Fig. 1 E). Thus, in the presence of cathepsin
inhibitors, anti-CD3 induces a cell-autonomous suicidal
death, as expected for a failure in CTL self-protection.
 
Rapid Activation-induced Death of Cytotoxic Effector Cells
Occurs in the Presence of Membrane-impermeant, Cathepsin
B–specific Inhibitors.
 
The experiments described above indicate
that activated mouse and human CD8
 
  
 
T cells die when in-
duced to degranulate in the presence of cathepsin inhibitors.
To define the cell types that are capable of undergoing this
death, purified subpopulations of human blood lymphocytes
were cultured under activating conditions to induce degran-
ulation. As shown in Fig. 2 A, human CD8
 
  
 
T cell blasts,
highly active as cytotoxic effector cells, died within 4 h
when incubated on anti-CD3–coated wells in the presence
of cathepsin inhibitors. On the other hand, resting human
CD8
 
  
 
T cells and CD4
 
  
 
blasts did not die when incubated
on wells coated with both anti-CD3 and anti-CD28. Highly
cytolytic CD56
 
  
 
cultured human NK cells showed a pro-
nounced death when triggered to degranulate with immobi-
lized anti-CD16 (34) in the presence of cathepsin inhibitors.
As with CTLs, these inhibitors showed no evidence of tox-
icity in the absence of the degranulating stimulus. Thus, the
lymphocyte death response after a degranulation stimulus in
the presence of cathepsin inhibitors reflects their cytotoxic
potential via the granule exocytosis pathway.
These cathepsin inhibitors are small hydrophobic pep-
tides that can readily permeate cells and inactivate intra-
cellular thiol proteases including cathepsins B, L, and H, as
well as calpain. However, cathepsin protection of degran-
ulating cytotoxic lymphocytes against perforin attack is
expected to occur in an extracellular location. Fig. 2 B shows
that the membrane-impermeant 13-kD protein cathepsin in-
hibitor cystatin C facilitates activation-induced CD8
 
  
 
T cell
Figure 1. Alloactivated mouse CD8   T cell
death induced by anti-CD3 in the presence of
cathepsin inhibitors. (A) CD8  T cells from B6
mice activated by a primary MLR culture were in-
cubated for 4 h with and without the indicated
cathepsin inhibitors on wells coated with anti-CD3
or anti-CD45 (filled bars) or control hamster or
mouse IgG (inset open bars). Cell death was mea-
sured microscopically by nuclear propidium iodide
staining (measuring membrane integrity, solid bars)
or apoptotic nuclear morphology using Hoechst
33342 (gray bars). The cathepsin inhibitors ZLLY-
DMK, ZFA-FMK, and controls GF-DMK and
ZF A-FMK, were used at final concentrations of
50  M. Error bars show SEM of triplicate samples.
(B) Murine-alloactivated CD8  MLR blasts were
incubated with 50  M cathepsin inhibitor ZLLY-
DMK in the presence of 10  g/ml IgG anti-Fas
antibody, 1 M concanamycin A (Ccm A), or 2.5
mM EGTA. Cell death was assessed after 4 h by
propidium iodide staining in anti-CD3– (solid bars)
or control hamster IgG–coated wells (inset open
bars). (C) Alloactivated CD8  MLR blasts from perforin knockout or gld mice were incubated 4 h with or without 50  M cathepsin inhibitor ZLLY-
DMK. Cell death by propidium iodide was measured in wells coated with anti-CD3 (solid bars) or control IgG (open inset bars). (D) Kinetics of death of
human CTL clone RS-56 induced by plate-bound anti-CD3 in the presence of 50  M cathepsin inhibitor ZFA-FMK.  , no anti-CD3 or ZFA-FMK.
(E) Density dependence of CTL death as in D, measured at 4 h.  , CTL incubated with 50  M ZFA-FMK on plate-bound anti-CD3;  , same as  
with 2   106 kD dextran added to a final concentration of 5% to increase medium viscosity to block fratricidal killing;  , anti-CD3 with no ZFA-FMK;
 , ZFA-FMK with no anti-CD3.497 Balaji et al.
suicide as well as ZLLY-DMK, arguing that cathepsin inhi-
bition at an extracellular location is sufficient for this death.
Although cathepsins B, L, and H generally have a simi-
lar proteolytic cleavage specificity, detailed structural stud-
ies of cathepsins B and L have recently allowed the design
of a new generation of highly selective inhibitors (35).
These compounds are based on the general thiol protease
inhibitor E64 with the covalently reactive epoxysuccinyl
moiety linked to peptides that bind selectively to the ac-
tive sites of these proteases. The cathepsin B–specific in-
hibitor CA074 is available as a cell-permeant methyl ester
(CA074Me) as well as the membrane-impermeant anionic
form (CA074; reference 36). As shown Fig. 2 C, both
CA074 and CA074Me facilitated CD8  T cell death after
TCR cross-linking. Concentrations of  1  M were suffi-
cient for these cathepsin B inhibitors, whereas concentra-
tions of  25  M were required in the case of ZLLY-
DMK and ZFA-FMK (unpublished data). In contrast to
the potent effect of the cathepsin B–specific inhibitor, the
cathepsin L–specific homologous epoxysuccinyl-based in-
hibitor CLIK 148 failed to induce suicide in degranulating
T cells at micromolar concentrations (Fig. 2 C). Thus,
these functional experiments indicate that surface cathep-
sin B is required for activation-induced suicide of cyto-
toxic effector cells.
NS-196 is another epoxysuccinyl-based cathepsin B–spe-
cific inhibitor, which was synthesized as a biotinylated
peptide affinity reagent and shown to be impermeable to
cell membranes (37). Similar to CA074, this reagent sensi-
tized CTLs to activation-induced suicide at submicromolar
concentrations (Fig. 2 D). Thus, two distinct, highly cathep-
sin B–specific membrane-impermeable inhibitors potently
showed this ability, implicating extracellular cathepsin B in
self-protection.
CTLs Die upon Target Cell Recognition in the Presence of
Surface Cathepsin B Inhibitor CA074. To test whether sur-
face cathepsin B inhibition causes CTLs to die upon target
cell recognition, we performed an experiment in which
either CTLs or target cells were labeled with 51Cr. Allo-
specific mouse CTLs that potently killed L1210 tumor tar-
gets in a 4-h assay (Fig. 3 A) were killed by incubation
with these target cells for 4 h in the presence of CA074
(Fig. 3 B). Thus, triggering the CTL TCR with antibodies
or antigen gives equivalent suicide when surface cathepsin
B is inhibited.
Previous experiments using the cathepsin inhibitor
ZFA-FMK as a control for caspase inhibitors showed that
it failed to inhibit CTL-mediated target lysis or apoptotic
injury (6, 38). When CA074 was tested for its ability to
block CTL-mediated target death in a standard 4-h assay,
little or no inhibition was found at concentrations up to
50  M (Fig. 3 C). If most of the target death in this assay
resulted from initial encounters of CTL with their targets,
this antigen-triggered suicide would not be expected to
influence levels of target lysis. However, when we later
examined target lysis in the same wells by replacing the
supernatants harvested at 4 h with fresh medium and
reharvesting after an additional overnight incubation,
CA074 was seen to have a clear inhibitory effect on this
delayed target lysis (Fig. 3 D). When calculated by lytic
units (horizontal shift in the curves), 10  M CA074 in-
hibits  75% of this late cytotoxicity. To control the pos-
sibility that CA074 exerts a delayed inhibition of CTL
function, the inhibitor was preincubated with CTL for
16 h before adding target cells. Averaging several experi-
ments of this type shows that CA074 inhibits delayed tar-
get death at  60%, compared with  20% inhibition dur-
ing a 4-h assay. Thus, surface cathepsin B inhibition
blocks CTL function, as expected for an agent that defeats
self-protection.
Cathepsin B Is Rapidly Expressed on the CTL Surface upon
TCR Stimulation. Using flow cytometry, cells from a hu-
man CD8  CTL clone were examined for surface expres-
sion of cathepsin B after a degranulation stimulus. Fig. 4
Figure 2. Activation-induced suicide of cytotoxic effec-
tors in the presence of membrane-impermeant cathepsin B
inhibitors. (A) Human CD8  T cell blasts, resting blood
CD8  cells, CD4  T cell blasts, and NK cells were incu-
bated for 4 h with and without 50  M cathepsin inhibitors
ZLLY-DMK or ZFA-FMK. Cell death was assessed by
propidium iodide from wells coated with control IgG
(open inset bars) or the indicated degranulating stimuli
(open bars). Striped bars, no inhibitor; solid bars, ZLLY-
DMK; gray bars, ZFA-FMK.(B) Alloactivated mouse
CD8  T cell blasts were incubated for 4 h on anti-CD3–
coated wells (solid bars) or control IgG (open inset bars)
with or without 10  M cystatin C or 50  M ZLLY-
DMK, and cell death was assessed by propidium iodide.
(C) Alloactivated CD8  BALB/c T cells were incubated
on wells coated with anti-CD3 (solid bars) or control IgG
(open inset bars) for 4 h in presence or absence of the indi-
cated cathepsin inhibitors and stained with propidium io-
dide. (D) Same conditions as in C, comparing NS-196 and
ZLLY-DMK.498 Cytotoxic Lymphocyte Self-Protection by Surface Cathepsin B
shows that nonstimulated CTL did not express significant lev-
els of surface cathepsin B, although it was minimally detectable
in some experiments. However, within 2 h after exposure to
plate-bound anti-CD3, cathepsin B was clearly increased with
a homogenous peak of positive cells. In contrast, cathepsin L
showed weak surface expression on unstimulated CTL, which
was not increased after CD3 cross-linking.
Because the association of active cathepsin B with tu-
mor cell surfaces has been shown to be dependent on di-
valent cations (22), we tested whether this was also the
case with CTL. Fig. 5, A and B, show that the EDTA
treatment that removes surface cathepsin B from tumor
cells also removes it from recently degranulated CTL. Fig.
5 C shows an experiment in which the released cathepsin
B was immunoprecipitated from supernatants after treating
such CTL under selective conditions for Ca 2 and Mg 2
chelation. Western blots of such supernatants (Fig. 5 C)
showed that the 32-kD “one-chain” form of cathepsin B
was only detectable when CTL had been precultured on
anti-CD3–coated wells to trigger degranulation, and when
they were subsequently incubated in Mg-EGTA to chelate
free calcium.
Western blots of human CTL lysates show that cathepsin
B expression in these cells occurs as either the 32-kD one-
chain form or the additionally processed 25-kD “two-
chain” form. In some CTL preparations these two forms
are expressed in roughly equal proportions, whereas in
other preparations one or the other isoforms is dominant.
In the experiment shown in Fig. 5, the whole CTL lysate
expresses  10 times more 25-kD cathepsin B, although the
32-kD form is visible in longer exposures.
CTL Surface Cathepsin B Is Enzymatically Active and the
Sole Target of NS-196. Because lysosomal cathepsin B might
be unstable and inactive at neutral pH, the hypothesis
Figure 3. CTL suicide during target cell lysis.
(A) Lysis of H-2d–bearing L1210 tumor cells by
H-2d–reactive CTL in a 4-h assay. (B) Lysis of
51Cr-labeled CTL (104/well) used in A when incu-
bated for 4 h with L1210 target cells in the pres-
ence of 10  M CA074.  , CA074;  , no inhibi-
tor. (C–D) H-2b–reactive CTL were mixed with
51Cr-labeled EL4 cells in the presence or absence
of 10  M CA074. After 4 h, 125  l supernatant
were harvested for counting (C) and replaced with
125  l of medium for  12 h of additional incuba-
tion. D shows the second harvest. As a toxicity
control for CA074 in D, the CTLs in C were in-
cubated with 10  M CA074 for 16 h before the
cytotoxicity assay with 51Cr-labeled EL-4 cells.  ,
no inhibitor;  , 10  M CA074. (E) Mean inhibi-
tion of CTL lytic activity from multiple experi-
ments like those shown in C and D, calculated by
lytic units (horizontal shift between cytotoxicity
dose response curves).
Figure 4. TCR cross-linking rapidly increases CTL surface expression
of cathepsin B, but not cathepsin L. (B and D) CD8  cloned human CTL
were incubated on surface-bound anti-CD3, or (A and C) isotype IgG for
2 h at 37 C. (A and B) Cells were then stained with anti-cathepsin B or
(C and D) with anti-cathepsin L antibody followed by FITC-anti–mouse
IgG (heavy lines). Dashed lines show staining by normal IgG controls.
Figure 5. Surface cathepsin B on TCR-activated CTL is released by
EGTA and is the single chain form. CD8  cloned human CTL were
stimulated with plate-bound anti-CD3 for 2 h at 37 C, washed with PBS,
and (A) incubated with PBS or (B) 0.53 mM EDTA in PBS for 10 min at
37 C. After washing, cells were incubated with anti-cathepsin B (heavy
line) followed by anti–mouse Ig-FITC (dashed line shows control with
no anticathepsin B). (C) Anti-CD3–treated CTL as in A and B were in-
cubated with 2 mM Mg-EGTA or Ca-EDTA in HBSS for 10 min at
37 C. Supernatants were analyzed by blotting with anti-cathepsin B. The
last lane shows whole CTL dissolved in SDS sample buffer and run di-
rectly (1/20 of the cell-equivalent input of other lanes).499 Balaji et al.
that it provides self-protection for cytotoxic lymphocytes
by cleaving perforin is open to question. On the other
hand, it has been shown that cathepsin B on the surface of
tumor cells is enzymatically active (23). We probed for the
activity of CTL surface cathepsin B by testing whether it is
reactive with the biotinylated cathepsin B–specific affinity
reagent NS-196, which sensitizes CTL to activation-
induced suicide (Fig. 2 D). This reagent undergoes covalent
reaction with the active site cysteine in a step that mimics
proteolysis. As shown by flow cytometry in Fig. 6 A, the
NS-196 reagent biotinylates resting CTL surfaces to a small
extent (variable in different experiments), but after degran-
ulation a greatly increased biotinylation is observed, as pre-
dicted if the immunoreactive cathepsin B (Fig. 4) is enzy-
matically active. Fig. 6 B shows streptavidin blots of
NS-196–treated CTL with and without degranulating stimuli.
NS-196 biotinylates a single 32-kD protein in untreated
CTL (compatible with the slight biotinylation seen in Fig. 6
A), and this band is greatly enhanced by the degranulation
stimulus. Immunodepletion of the lysate with anticathepsin
B specifically removes the biotinylated 32-kD band, dem-
onstrating that the only protein significantly labeled by NS-
196 during its inactivation of self-protection is cathepsin B.
Cathepsin B Cleaves Perforin. The above data clearly im-
plicate surface cathepsin B in cytotoxic lymphocyte self-
protection, but do not directly address the molecular target
of cathepsin B. Given previous data showing that mem-
brane-associated perforin is highly susceptible to proteolysis
(26), and the proximity of degranulated surface cathepsin B
to perforin associated with effector cell membranes, per-
forin is an obvious candidate. To see if this protease is capa-
ble of degrading perforin, we incubated purified cathepsin
B with CTL extracts containing perforin and monitored
digestion with Western blots. The results show that per-
forin is efficiently digested by cathepsin B, a process that is
inhibited by CA074 (Fig. 7).
Discussion
The experiments described above provide strong support
for the model of cytotoxic lymphocyte self-protection
shown in Fig. 8. The essential feature of this model is that
self-protection is provided by surface membrane cathepsin
B expressed as a result of degranulation. The data we have
presented support this model with functional evidence that
cathepsin B inhibitors sensitize cytotoxic lymphocytes to
Figure 6. Surface cathepsin B on TCR-acti-
vated T cells is active and the target of NS-196.
(A) Detection of biotinylated NS-196 on the
CTL surface after degranulation. Flow cytome-
try of CD8  cloned human CTL RS-56 after
culture on wells coated with anti-CD3 or iso-
tope control for 2 h, followed by treatment
with or without 1  M NS-196, which was de-
tected by FITC-streptavidin. (B) Identification
of cathepsin B as the molecular target of NS-
196. CTL clone RS-56 was incubated for 2 h
on anti-CD3– or IgG-coated wells, followed
by incubation with or without 0.1  M NS-
196. Cells were lysed with Triton X-100 and
immunodepleted with beads containing anti-
cathepsin B antibody or control rabbit IgG.
The remaining lysate was run on a 12% nonre-
duced SDS gel, blotted onto nitrocellulose,
probed with Streptavidin-HRP, and developed using ECL. The right lane shows the biotinylation pattern when the whole CTL lysate was labeled with
0.1  M NS-196 and run directly (1/10 of the cell-equivalent input of other lanes).
Figure 7. Perforin cleavage by cathepsin B. (A) Perforin
from CTL extracts was treated with 258 ng/ml purified
cathepsin B for various times and analyzed by blotting with
anti-perforin antibody. (B) Mean densitometric analysis of
perforin degradation by cathepsin B. Three experiments
are shown.500 Cytotoxic Lymphocyte Self-Protection by Surface Cathepsin B
activation-induced suicide, as well as evidence for the cell
surface expression of active cathepsin B triggered by de-
granulation. This model provides a rational explanation for
the considerable literature bearing on cytotoxic lympho-
cyte self-protection (8). Because it postulates that expres-
sion of the critical cathepsin B self-protective molecule is
local and transient, cytotoxic lymphocytes would be vul-
nerable to fratricidal attack. The model postulates that self-
protection occurs before perforin-mediated membrane
damage, which is the most upstream of the series of damag-
ing events leading to target cell death.
Our functional data show that cytotoxic lymphocytes in-
duced to degranulate in the presence of membrane-imper-
meant cathepsin B–specific protease inhibitors die rapidly
via a perforin-dependent suicide process. T his death pro-
cess occurs in cytotoxic T and NK cells, but not in T cells
lacking the granule exocytosis cytotoxicity pathway. This
suicide does not occur in perforin-deficient CTL and is in-
hibited by the granule proton pump poison concanamycin
A and calcium chelation, all of which implicate the granule
exocytosis cytotoxicity pathway.
Extracellular cathepsin B is implicated by the data in Fig.
2, which shows that two different membrane-impermeant
cathepsin B–specific protease inhibitors sensitize CTL to
this activation-induced suicide. Cathepsin B is the only
protease inactivated by all the inhibitors sensitizing CTL
activation suicide, which include general thiol cathepsin in-
hibitors such as fluoromethyl ketones (28), diazomethyl ke-
tones (39), epoxysuccinyl peptide compounds (35), and
cystatins (40). Other cysteine proteases expressed in mam-
malian cells, such as caspases and calpains, do not react with
most of these inhibitors. The thiol cathepsin family is asso-
ciated with lysosomes and shares sequence homology, but
different family members display different enzymatic prop-
erties and tissue expression patterns (41, 42). Lymphocytes
express the general lysosomal endoprotease cathepsins B,
H, and L, as well as the exopeptidase cathepsin C (DPPI).
Cytotoxic lymphocytes also express cathepsin W (43–46),
whose enzymatic properties remain undescribed. However,
CA074 and NS-196 are cathepsin B–specific reagents and
virtually inactive against cathepsins H or L (36, 37, 47, 48).
As these compounds are the most potent inhibitors in sen-
sitizing CTL activation suicide, the functional data impli-
cate cathepsin B as the major component of CTL self-pro-
tection. Although cathepsin W, with its uncharacterized
enzyme activity, could be the target of CA074 and NS-
196, the experiments discussed below appear to rule out
this possibility. However, our data do not rigorously ex-
clude the possible role of other minor NS-196–reactive ca-
thepsins in cytotoxic lymphocyte self-protection.
The second line of evidence implicating cathepsin B
comes from our studies of its surface expression on CTL,
which indicate that this protease is minimally expressed on
the surface of resting CTL, but rapidly detectable there af-
ter degranulation (Fig. 4). This is compatible with cathep-
sin B secretion from the secretory granule, where it nor-
mally resides as one of the lysosomal granule components.
The issue of how cathepsin B associates with the surface
membrane is not fully resolved. This protein has no hydro-
phobic membrane domain and is normally found as a solu-
ble protein in lysosomes, but active cathepsin B is expressed
on the surface of some tumor cells (23). Because in the lat-
ter case the protease was released by EDTA, we performed
the experiment shown in Fig. 5, which shows that cathep-
sin B bound to degranulated CTL is released by calcium
chelation. However, calcium is not known to bind to
cathepsin B and it is not clear what CTL surface compo-
nent might be involved. A surface complex of procathepsin
B and annexin II as found on tumor cell surfaces (22)
would not be relevant to cytotoxic lymphocyte self-protec-
tion, as the proenzyme lacks the critical proteolytic activity.
In our survey of various human CTL lines, Western blots
detected both the 32-kD one-chain and the 25-kD two-
chain cathepsin B in varying proportions in lysates of dif-
ferent lines (unpublished data). However, the cathepsin B
eluted off these degranulated CTL with EGTA always con-
sisted of only the 32-kD form (e.g., Fig. 5), which was also
the only NS-196–reactive molecule in CTL lysates (e.g.,
Fig. 6). These experiments show that the surface-expressed
32-kD cathepsin B in CTL is enzymatically active and
seems to be specifically selected for surface expression, even
in cells expressing a large amount of 25-kD cathepsin B
(Fig. 5). One possible explanation is that a subpopulation of
cathepsin B molecules in cytotoxic lymphocyte granules is
bound to the granule membrane and that the molecular in-
teractions providing membrane attachment also provide
protection against the additional processing cleavages, giv-
ing rise to the two-chain form of cathepsin B in those gran-
ules. In any case, the role of cathepsin B in self-protection
is definitively established by the experiment shown in Fig.
6, in which the NS-196 reaction conditions that defeat
self-protection (Fig. 2 D) were shown to result in a single
biotinylated 32-kD protein that was reactive with anti-
cathepsin B.
The model in Fig. 8 proposes that cathepsin B cleaves
membrane-associated perforin before it forms a pore. This
is based on previous studies indicating that perforin initially
binds to membranes via a reversible intermediate (14, 24,
Figure 8. Surface cathepsin B model for cytotoxic lymphocyte self-
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25) that is highly susceptible to proteolysis by trypsin, chy-
motrypsin, and pronase (14, 26), proteases with distinctly
different cleavage specificities. Because the surface-associ-
ated forms of cathepsin B and perforin appear to have dif-
ferent properties from the soluble proteins, it is difficult to
experimentally mimic the local environment illustrated in
Fig. 8. However, the experiment in Fig. 7 shows that
cathepsin B readily cleaves perforin and that having both
the protease and perforin associated with the same mem-
brane would greatly enhance the efficiency of perforin
degradation.
One other molecular model for cytotoxic lymphocyte
self-protection that has been proposed involves the serpin
granzyme B inhibitor, PI-9 (49, 50). This protein is ex-
pressed in the cytoplasm of cytotoxic lymphocytes and
other cells, such as dendritic cells (51), and has been shown
to be capable of blocking lymphocyte cytotoxicity when
overexpressed in MCF-7 cells (50). Although it is possible
that PI-9 plays a role in cytotoxic lymphocyte self-protec-
tion, its role remains speculative because (a) there is no di-
rect evidence for a PI-9 role in self-protection, and (b)
PI-9 specifically blocks granzyme B, and cytotoxic lympho-
cytes lacking granzyme B retain potent cytotoxic activity
even if their ability to induce target apoptosis is diminished
(52). Unless PI-9 protein is polarized within the effector
cytoplasm after target recognition, it is hard to envision
how this granzyme B inhibitor could provide self-protec-
tion while allowing fratricide. Nevertheless, PI-9 or other
internal protease inhibitors could contribute to effector
self-protection by mechanisms that are compatible with
and complementary to surface cathepsin B protection.
It is possible that surface proteases, including cathepsin
B, play a role in controlling the in vivo susceptibility of
various cells to cytotoxic lymphocyte death. In many cases,
virally infected cells decrease their recognizability by cyto-
toxic lymphocytes by either suppressing surface MHC or
surface peptide expression in the case of CTL, or by inter-
fering with NK cell activation (53). An alternative means of
resisting cytotoxic lymphocyte attack is to induce resistance
to the lethal damage itself. One such example may be the
human leukemia cell line ML-2, which is recognized by
NK cells but resistant to killing by either NK cells or per-
forin, apparently because of defective perforin binding (54).
Expression of a surface protease such as cathepsin B could
explain such tumor cell resistance to cytotoxic lympho-
cytes. Although the expression of surface cathepsins on tu-
mor cells has been thought of as a means to free cells from
tissue adhesions and allow metastasis (55), our results sug-
gest that this protease may also allow resistance to attack by
cytotoxic lymphocytes, which recent experiments clearly
show are important in tumor surveillance (56).
Our finding that CTL and NK cells utilize surface cathep-
sin B for self-protection opens the possibility that its activ-
ity could be subject to physiological regulation. Its inhibi-
tion in vivo may lead to activation-induced suicide
accompanying degranulation similar to what we have dem-
onstrated experimentally. For example, Figs. 1 and 2 show
a 10–18% background activation-induced death detectable
at 4 h with both CTL and NK cells in the absence of added
cathepsin inhibitors (Figs. 1 and 2). This death seems com-
patible with the slow perforin-dependent activation-
induced death previously reported with activated CD8  T
cells in vitro and in vivo (57, 58), and may reflect a physio-
logical pathway for deleting CD8  T cells. The failure of
normal CD8  T cell homeostasis after chronic viral infec-
tion in perforin knockout mice (59) suggests that CTL may
kill themselves or each other when antigen persists. The fa-
tal hyperproliferative syndrome in humans with perforin
defects is characterized by infiltrating activated T cells and
macrophages (4), suggesting that CTL cytotoxicity nor-
mally restrains these populations, possibly by third-party,
fratricidal, and suicidal mechanisms. Thus, the role of sur-
face cathepsin B in self-protection raises the question of
whether naturally occurring protease inhibitors may com-
promise the efficiency of self-protection in vivo and there-
fore modulate T cell homeostasis.
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